| 1.95 -0.03 (-1.52%) | 06-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.47 | 1-year : | 2.88 |
| Resists | First : | 2.11 | Second : | 2.47 |
| Pivot price | 1.6 |
|||
| Supports | First : | 1.71 | Second : | 1.46 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.62 |
| MA(100) : | 2.43  |
MA(250) : | 3.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 56.4 |
| RSI | RSI(14): 62.4 |
|||
| 52-week | High : | 6.78 | Low : | 1.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NBP ] has closed above the upper band by 7.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.12 - 2.13 | 2.13 - 2.13 |
| Low: | 1.68 - 1.69 | 1.69 - 1.69 |
| Close: | 1.97 - 1.98 | 1.98 - 1.99 |
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Tue, 30 Jun 2026
Fu Wei at NovaBridge (NBP) awarded RSUs and long-dated options - Stock Titan
Mon, 29 Jun 2026
NovaBridge Biosciences (NBP) Appoints Srishti Gupta as New CEO - GuruFocus
Mon, 29 Jun 2026
NovaBridge Biosciences Names Dr. Srishti Gupta CEO to Lead Clinical Development Strategy - citybiz
Mon, 29 Jun 2026
Leadership shake-up at NovaBridge (Nasdaq: NBP) as Srishti Gupta becomes CEO - Stock Titan
Mon, 29 Jun 2026
NovaBridge taps physician-executive Dr. Gupta as CEO July 1 - Stock Titan
Mon, 29 Jun 2026
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 14.4 (%) |
| Held by Institutions | 39.9 (%) |
| Shares Short | 4,160 (K) |
| Shares Short P.Month | 4,940 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.9 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -4.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|